Publications

  1. Badar T, Nanaa A, Atallah E, Shallis RM, Craver EC, Li Z, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy GSG, Zeidan AM, Kota V, Patnaik MM, Litzow MR. Prognostic impact of 'multi-hit' versus 'single hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases. Haematologica. 2024 May 30 [Epub ahead of print]
    View PubMed
  2. Kjellesvig S, Zaworski E, Saliba AN. Acute Myelomonocytic Leukemia Presenting as Fournier's Gangrene. WMJ. 2024 May; 123 (2):131-134
    View PubMed
  3. Murthy GSG, Saliba AN, Szabo A, Harrington A, Abedin S, Carlson K, Michaelis L, Runaas L, Baim A, Hinman A, Maldonado-Schmidt S, Venkatachalam A, Flatten KS, Peterson KL, Schneider PA, Litzow M, Kaufmann SH, Atallah E. A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia. Haematologica. 2024 Apr 4 Epub 2024 Apr 04
    View PubMed
  4. Johnson IM, Karrar O, Rana M, Iftikhar M, Chen S, McCullough K, Saliba AN, Al-Kali A, Alkhateeb H, Begna K, Litzow M, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Hermann J, Tefferi A, Gangat N. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. Br J Haematol. 2024 Apr; 204 (4):1232-1237 Epub 2024 Feb 04
    View PubMed
  5. Jia J, Ji W, Saliba AN, Csizmar CM, Ye K, Hu L, Peterson KL, Schneider PA, Meng XW, Venkatachalam A, Patnaik MM, Webster JA, Smith BD, Ghiaur G, Wu X, Zhong J, Pandey A, Flatten KS, Deng Q, Wang H, Kaufmann SH, Dai H. AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death. Cell Death Differ. 2024 Apr; 31 (4):405-416 Epub 2024 Mar 27
    View PubMed
  6. Steinauer N, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, Saliba AN, Torghabeh M, Litzow MR, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Yi CA, Tefferi A, Gangat N. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent. Haematologica. 2024 Mar 28 [Epub ahead of print]
    View PubMed
  7. Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024 Feb; 99 (2):193-202 Epub 2023 Dec 10
    View PubMed
  8. Lewis AR, Choong GM, Cathcart-Rake E, Florez N, Durani U, Yadav S, Fuentes H, Sorensen K, Childs DS, Saliba A, Paludo J, Hobday TJ. Preparing Hematology/Oncology Fellows for Success: Implementing an Annual Career Development and Research Retreat. J Cancer Educ. 2024 Feb; 39 (1):58-64 Epub 2023 Oct 17
    View PubMed
  9. Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Saliba A, Torghabeh MH, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Badar T, Foran J, Palmer J, Sproat L, Yi CA, Tefferi A. Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia. Haematologica. 2024 Jan 1; 109 (1):187-292 Epub 2024 Jan 01
    View PubMed
  10. Saliba AN, Musallam KM, Taher AT. How I treat non-transfusion-dependent beta-thalassemia. Blood. 2023 Sep 14; 142 (11):949-960
    View PubMed
  11. Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2023 Jun 13; 7 (11):2360-2363
    View PubMed
  12. Badar T, Litzow MR, Shallis RM, Patel A, Saliba AN, Burkart M, Bewersdorf JP, Stahl M, De Camargo Correia GS, Guru Murthy GS, Abaza Y, Duvall A, Bradshaw D, Kota V, Dinner S, Goldberg AD, Palmisiano N, Al Kali A, Atallah E. Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer. 2023 Mar 15; 129(6):934-945. Epub 2022 Dec 21.
    View PubMed
  13. El Hasbani G, Saliba AN, Uthman I, Taher AT. Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis. Blood Rev. 2023 Mar; 58:101015 Epub 2022 Sept 16
    View PubMed
  14. Bizri M, Ibrahim N, El Hayek S, Saliba A, Ehlers SL, Ostroff JS, Maalouf F, Taher A. Challenges in implementing psycho-oncology services in Arab low- and middle-income countries: Lessons learned from Lebanon. Psychooncology. 2023 Jan; 32 (1):174-178 Epub 2022 Aug 17
    View PubMed
  15. King JM, Akel R, Saliba AN, Wei C, Anouti B, Manchanda N, Sinex NC, Grethlein SJ, Goldman M. Innovation in Resident Core Oncology Education: Switching from an Inpatient Ward Rotation to a Hybrid Model of Inpatient Consultations and Outpatient Clinics. J Cancer Educ. 2022 Dec; 37 (6):1768-1772 Epub 2021 May 14
    View PubMed
  16. Peseski AM, Saliba AN, Althouse SK, Sayar H. Does Race Play a Role in Complications and Outcomes of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms? Hematol Oncol Stem Cell Ther. 2022 Jun 1; 15 (2):30-38 Epub 2022 June 01
    View PubMed
  17. Saliba AN, Gangat N. Accelerated and blast phase myeloproliferative neoplasms. Best Pract Res Clin Haematol. 2022 Jun; 35(2):101379. Epub 2022 Aug 30.
    View PubMed
  18. Hwang SR, Saliba AN, Wolanskyj-Spinner AP. Immunotherapy-associated Autoimmune Hemolytic Anemia. Hematol Oncol Clin North Am. 2022 Apr; 36(2):365-380.
    View PubMed
  19. Hickman AD, Saliba AN, Nowakowski GS. 67-Year-Old Woman With Diarrhea and Weight Loss. Mayo Clin Proc. 2022 Feb; 97(2):364-369.
    View PubMed
  20. Csizmar CM, Saliba AN, Swisher EM, Kaufmann SH. PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. Cancers (Basel). 2021 Dec 20; 13(24).
    View PubMed
  21. Ezzeddine FM, Saliba AN, Jain V, Villarraga HR, Herrmann J, Asirvatham SJ, Cha YM. Outcomes of cardiac resynchronization therapy in patients with chemotherapy-induced cardiomyopathy. Pacing Clin Electrophysiol. 2021 Apr; 44 (4):625-632 Epub 2021 Mar 15
    View PubMed
  22. Bezerra ED, Lasho TL, Finke CM, Saliba AN, Elliott MA, Pardanani AD, Gangat N, Mangaonkar AA, Ketterling RP, Tefferi A, Solary E, Patnaik MM. CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. Blood Cancer J 2021 Mar 11; 11 (3):54
    View PubMed
  23. Xie Z, Nanaa A, Saliba AN, He R, Viswanatha D, Nguyen P, Jevremovic D, Greipp P, Salama ME, Gangat N, Alkhateeb HB, Tefferi A, Litzow M, Patnaik M, Shah M, Al-Kali A. Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer J 2021 Mar 1; 11 (3):43 Epub 2021 Mar 01
    View PubMed
  24. Grach SL, Saliba AN, Costello BA. 40-Year-Old Man With Left Leg Swelling and Abdominal Pain. Mayo Clin Proc. 2021 Mar; 96 (3):782-787
    View PubMed
  25. Patel SR, Saliba AN, Steel S, Liewluck T, Mahipal A. Metastatic Colon Cancer Presenting With Immune-mediated Necrotizing Myopathy. Clin Colorectal Cancer. 2021 Mar; 20 (1):e71-e73 Epub 2020 Aug 29
    View PubMed
  26. Saliba AN, John AJ, Kaufmann SH. Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia. Cancer Drug Resist. 2021; 4(1):125-142. Epub 2021 Mar 19.
    View PubMed
  27. Saliba AN, Ferrer A, Gangat N, Pruthi RK, Tefferi A, Higgins A, Bezerra ED, Buglioni A, Salama ME, Klee EW, Pinto E Vairo F, Mangaonkar A, Majerus J, Chen D, Patnaik MM. Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients. Br J Haematol 2020 Sep; 190 (5):e316-e320 Epub 2020 June 22
    View PubMed
  28. Saliba AN, Atoui A, Labban M, Hamade H, Bou-Fakhredin R, Mufarrij A, Taher AT. Thalassemia in the emergency department: special considerations for a rare disease. Ann Hematol. 2020 Sep; 99 (9):1967-1977 Epub 2020 July 03
    View PubMed
  29. Sleiman J, Tarhini A, Bou-Fakhredin R, Saliba AN, Cappellini MD, Taher AT. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. Int J Mol Sci. 2018 Jan 8; 19 (1) Epub 2018 Jan 08
    View PubMed
  30. Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program. 2017 Dec 8; 2017 (1):265-271
    View PubMed
  31. Taher AT, Saliba AN, Kuo KH, Giardina PJ, Cohen AR, Neufeld EJ, Aydinok Y, Kwiatkowski JL, Jeglinski BI, Pietropaolo K, Berk G, Viprakasit V. Safety and pharmacokinetics of the oral iron chelator SP-420 in beta-thalassemia. Am J Hematol. 2017 Dec; 92 (12):1356-1361 Epub 2017 Oct 31
    View PubMed
  32. Saliba AN, Taher AT. Morbidities in non-transfusion-dependent thalassemia. Ann N Y Acad Sci. 2016 Mar; 1368 (1):82-94
    View PubMed
  33. Tamim H, Habbal M, Saliba A, Musallam K, Al-Taki M, Hoballah J, Jamali S, Taher A. Preoperative INR and postoperative major bleeding and mortality: A retrospective cohort study. J Thromb Thrombolysis. 2016 Feb; 41 (2):301-11
    View PubMed
  34. Saliba AN, El Rassi F, Taher AT. Clinical monitoring and management of complications related to chelation therapy in patients with beta-thalassemia. Expert Rev Hematol. 2016; 9 (2):151-68 Epub 2015 Dec 19
    View PubMed
  35. Saliba AN, Taher AT, Tamim H, Harb AR, Mailhac A, Radwan A, Jamali FR. Impact of Resident Involvement in Surgery (IRIS-NSQIP): Looking at the Bigger Picture Based on the American College of Surgeons-NSQIP Database. J Am Coll Surg. 2016 Jan; 222 (1):30-40 Epub 2015 Oct 27
    View PubMed
  36. Amid A, Saliba AN, Taher AT, Klaassen RJ. Thalassaemia in children: from quality of care to quality of life. Arch Dis Child. 2015 Nov; 100 (11):1051-7 Epub 2015 Aug 19
    View PubMed
  37. Saliba A, Taher A. Iron overload in transfusion-dependent thalassemia. Hematology. 2015 Jun; 20 (5):311-2
    View PubMed
  38. Saliba AN, Harb AR, Taher AT. Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med. 2015; 6:197-209 Epub 2015 June 17
    View PubMed